Oral ibandronate preceded by an intravenous (i.v.) ibandronate loading dose in patients with breast cancer and bone metastases or multiple myeloma:: phase III results

被引：0

作者：

Bergström, B

Lichinitser, M

Andreeva, N

Budde, M

Body, JJ

机构：

[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

[2] NN Blokhin Russian Canc Res, Moscow, Russia

[3] Semashko Cent Clin Hosp, Moscow, Russia

[4] F Hoffmann La Roche & Cie AG, Basel, Switzerland

[5] Univ Libre Bruxelles, Brussels, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：744S / 744S

页数：1

共 50 条

[1] Effect on bone markers of a single intravenous (i.v.) ibandronate infusion followed by daily oral ibandronate in patients with multiple myeloma or breast cancer and bone metastases
Bergström, B
Lichinitser, M
Andreeva, N
Garnero, P
Body, J
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P62 - P62
[2] Safety of intravenous (i.v.) and oral ibandronate for up to 4 years in patients with breast cancer and bone metastases
Tripathy, D
Body, J
Bergström, B
BONE, 2005, 36 : S210 - S211
[3] Oral ibandronate treatment preceded by a single rapid dose of intravenous (i.v.) ibandronate rapidly decreases serum-CTX a marker of bone resorption in patients with metastatic bone disease due to multiple myeloma and breast cancer
Bergström, B
Lichinitser, M
Andreeva, A
Budde, M
Garnero, P
Body, J
BONE, 2005, 36 : S212 - S212
[4] Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer
Macpherson, Iain R.
Bray, Caroline
Hopkins, Carol
Hannon, Rosemary A.
Lewsley, Liz-Anne
Ritchie, Diana M.
Canney, Peter
CLINICAL BREAST CANCER, 2015, 15 (02) : 117 - 127
[5] Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases:: Results from a comparative phase
Body, JJ
Lichinitser, M
Tjulandin, SA
Budde, M
Bergström, B
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 12S - 12S
[6] Comparative reductions in bone turnover markers with oral ibandronate and intravenous (i.v.) zoledronic acid in patients with bone metastases from breast cancer
Body, J
Lichinitser, M
Tjulandin, S
Garnero, P
Bergström, B
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P67 - P67
[7] Intravenous (i.v.) and oral ibandronate reduce the risk of skeletal-related events (SREs) in patients with breast cancer and bone metastases
Tripathy, D
Bergström, B
BONE, 2005, 36 : S211 - S212
[8] Oral ibandronate decreases markers of bone resorption to the same extent as intravenous (i.v.) zoledronic acid in patients with bone metastases from breast cancer:: Results from a comparative phase III trial
Body, J
Lichinitser, M
Tjulandin, S
Garnero, P
Bergström, B
BONE, 2005, 36 : S212 - S213
[9] Renal safety of intravenous (i.v.) ibandronate in patients with breast cancer and bone metastases for up to 4 years of treatment:: Clinical trial results
Diel, IJ
Body, J
Bergström, B
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P60 - P61
[10] Safety of intravenous (i.v.) and oral ibandronate for up to 4 years in patients with metastatic breast cancer
Pecherstorfer, Martin
Bergstroem, Bengt
ANNALS OF ONCOLOGY, 2004, 15 : 49 - 49

← 1 2 3 4 5 →